Could a tiny dose of radiation tame skin cancer lesions?
NCT ID NCT03398161
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether ultra low dose radiation can control skin lesions in people with mycosis fungoides, a type of lymphoma. About 50 participants will receive very low doses of radiation to their skin lesions. The goal is to see if this gentler approach works as well as standard radiation but with fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ultra low dose radiation therapy
- What this could lead to
- If successful, this could offer a gentler radiation option that controls skin lesions in mycosis fungoides with fewer side effects.
- What could go wrong
- This is a small, early-phase trial (50 people) testing a lower radiation dose, so it may not work as well as standard doses or may still cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2018
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with pathologically confirmed MF with cutaneous involvement. * Patients must have clinically measurable disease of at least 1 lesion on physical (skin) exam. * If a patient has a prior pathological diagnosis of MF and is clinically diagnosed with a new lesion, the new lesion is eligible for enrollment without additionally biopsy confirmation. * Lesions of any surface span as long as =\< 1 cm in maximal height measured from the skin surface for which local control is desired are eligible; a single patient may have multiple eligible lesions that are individually enrolled for the study. * All stages of disease (IA through IVB) where radiation therapy is being considered for local control are eligible. Patients who are concomitantly undergoing systemic therapy for more advanced stage disease are eligible. * Patients who are concomitantly undergoing systemic therapy for more advanced stage disease are eligible. * Female patients of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin \[hCG\]) within 2 weeks of protocol entry if the patient is unsure of their pregnancy status. Patient signature declaring that they are not pregnant on the informed consent for treatment that is used in the Department of Radiation Oncology is also an acceptable substitution for a serum pregnancy test. * Patients who are receiving or are planned to start topical chemotherapeutics, retinoids or imiquimod to other lesions that are not planned for enrollment are eligible; however, the lesion being considered for enrollment should not be under active therapy with these topical agents immediately prior to enrollment. * Use of topical chemotherapeutics, retinoids or imiquimod on the lesion that is a candidate for enrollment must be halted at least 24 hours prior to enrollment in the study. Exclusion Criteria: * Pregnant patients do not meet inclusion criteria for radiation therapy. * Patients who subsequently become pregnant may continue follow up within the protocol, but a negative urine pregnancy test will need to be obtained before additional lesions may be enrolled. * Patients with active lupus or scleroderma * Lesions with a height \> 1 cm measured from the skin surface are not eligible for this protocol.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Localized skin lesion are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Pairing a steroid with lymphoma gel may prevent painful skin reactions
- Can a daily mood diary reveal how steroids affect emotions?
- Can blood and skin markers predict lymphoma outcomes?
- Can an eczema cream fight a rare skin cancer?
- Skin gel targets immune signals in rare lymphoma
- Could an ALS drug clear the fog of chemo brain?